Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEâ3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEâ3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk).
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Near-term support ⢠First resistance zone Support Level: $19.0-$18.9 Resistance Level: $20.6-$21.5 CAPR remains in a clear short-term downtrend, with price stabilizing near $19.0-$18.9 but needing a reclaim of $21.5 to signal any real easing in selling pressure.
AI Summary
CAPR has evolved from a speculative DMD biotech into a near-term FDA catalyst with meaningful clinical de-risking, a $279M cash runway into late 2027, and launch readiness in place, but the stock remains a binary one-product bet until the July 29 advisory committee and Aug. 22 PDUFA resolve approval, label, and commercialization risk.
Description
Capricor Therapeutics is a clinical-stage biotechnology company developing cell- and exosome-based therapies for a range of diseases. Its lead candidate, CAP-1002, has completed a Phase III trial in late-stage Duchenne muscular dystrophy and is in Phase II testing for SARSâCoVâ2ârelated cytokine storm; the pipeline also includes a preclinical program for trauma-related injuries and vaccine candidates targeting COVIDâ19. The company outsources clinical manufacturing of CAP-1002 to Lonza Houston, was founded in 2005, and is based in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | CAPR | Capricor Therapeutics, Inc. | High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEâ3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEâ3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk). | Closed | -6.6% |